Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted radiopharmaceutical therapies for cancer. The company operates within the biotechnology and oncology therapeutics industries, with a particular emphasis on precision cancer treatment using proprietary phospholipid ether (PLE) cancer-targeting technology. Its core strategy is to selectively deliver radioisotopes or other cytotoxic agents directly to cancer cells while minimizing damage to healthy tissue.
The company’s primary revenue drivers are its oncology drug candidates, which are currently in clinical development rather than commercial sale. Cellectar primarily serves oncology patients and healthcare providers through clinical trials, with its key markets centered on hematologic malignancies and solid tumors. Founded in 2004 and headquartered in New Jersey, the company has evolved from early-stage research into a focused radiopharmaceutical developer with multiple clinical and preclinical programs targeting rare and hard-to-treat cancers.
Business Operations
Cellectar’s operations are centered on its proprietary PLE platform, which is designed to exploit metabolic and structural differences between cancer cells and normal cells. This platform underpins the company’s lead clinical assets, including CLR 131, a targeted radiotherapeutic conjugated with iodine-131, and CLR 121225, an alpha-emitting radiopharmaceutical candidate. The company generates value through internal research and development, regulatory advancement of its drug candidates, and potential future licensing or commercialization opportunities.
Operationally, Cellectar conducts research, preclinical development, and clinical trial management primarily in the United States, while also engaging international clinical sites depending on trial design. The company does not currently operate manufacturing at commercial scale and relies on third-party contract research organizations, clinical trial partners, and isotope suppliers. Cellectar does not report material joint ventures, but it maintains collaborative relationships with academic institutions and clinical investigators to support its development programs.
Strategic Position & Investments
Cellectar’s strategic direction is focused on advancing its lead radiopharmaceutical programs through clinical development and regulatory pathways, particularly for indications with high unmet medical need. CLR 131 has been evaluated in multiple clinical studies targeting relapsed or refractory multiple myeloma and other B-cell malignancies, positioning the company within the growing radiopharmaceutical oncology segment. The company continues to invest in expanding its pipeline using the PLE platform with both beta- and alpha-emitting isotopes.
The company’s investments are primarily internal, directed toward clinical trials, regulatory engagement, and intellectual property development rather than large-scale acquisitions. Cellectar has not announced major transformative acquisitions but continues to build a portfolio of wholly owned drug candidates derived from its proprietary targeting technology. Emerging areas of focus include next-generation radiotherapeutics and potential combination strategies with other oncology treatments, subject to clinical validation.
Geographic Footprint
Cellectar Biosciences is headquartered in New Jersey, with principal operations and corporate management based in the United States. Its clinical development activities are largely U.S.-focused, though certain trials have included or may include international sites depending on regulatory and patient enrollment considerations. The company does not maintain significant physical infrastructure outside the U.S.
Despite its limited physical footprint, Cellectar’s operational influence extends internationally through clinical trial participation, scientific collaboration, and engagement with global regulatory standards for radiopharmaceutical development. Its future geographic expansion is expected to depend on clinical success, regulatory approvals, and potential commercialization or partnership strategies in North America, Europe, and other oncology markets.
Leadership & Governance
Cellectar is led by an experienced executive team with backgrounds in biotechnology, oncology drug development, and corporate finance. The leadership emphasizes disciplined capital allocation, scientific rigor, and the advancement of targeted cancer therapies addressing unmet clinical needs. The company operates under a traditional public-company governance structure, overseen by a board of directors with industry and financial expertise.
Key executives include:
- James V. Caruso – President and Chief Executive Officer
- Mark R. Jones – Chief Financial Officer
- David A. Ruggiero – Chief Medical Officer
- Tracy R. Flynn – Senior Vice President, Clinical Development
The leadership’s strategic vision centers on leveraging the company’s proprietary targeting platform to create differentiated radiopharmaceutical assets, advance them efficiently through clinical development, and ultimately deliver meaningful therapeutic options for cancer patients.